Outlook Therapeutics (NASDAQ:OTLK) Announces Quarterly Earnings Results

Outlook Therapeutics (NASDAQ:OTLK) posted its earnings results on Friday. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Price Performance

Shares of OTLK traded up $0.08 during mid-day trading on Friday, reaching $1.78. The stock had a trading volume of 413,239 shares, compared to its average volume of 694,927. The business’s fifty day moving average is $3.88 and its 200 day moving average is $5.94. Outlook Therapeutics has a 52-week low of $0.87 and a 52-week high of $12.85. The firm has a market cap of $42.04 million, a price-to-earnings ratio of -0.17 and a beta of 0.47.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on OTLK shares. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, November 29th. BTIG Research cut their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Finally, Ascendiant Capital Markets decreased their price target on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Outlook Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $42.34.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.